Chengdu Egret Pharmaceutical Technology

Chengdu Egret Pharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of breakthrough small molecule therapeutics. Headquartered in Chengdu, China, the company specializes in precision oncology, particularly addressing drug resistance in lung cancer and other solid tumors. The company utilizes a robust R&D platform that integrates structure-based drug design and Proteolysis Targeting Chimera (PROTAC) technologies. Its lead candidate, EGR-2688, is a fourth-generation EGFR inhibitor currently in clinical trials designed to overcome the C797S mutation in non-small cell lung cancer. Beyond EGFR inhibitors, the company's pipeline includes programs targeting hormone receptors and other key drivers of cancer progression. Chengdu Egret aims to provide more effective treatment options for patients who have developed resistance to existing standard-of-care therapies.